



## **Janine Quinter**

Medizinische Onkologie und Hämatologie · Dept. I

### **Contact**

Janine Quinter  
St. Gallen

T +41 71 494 1099  
Janine.Quinter@kssg.ch

### **Units**

Medizinische Onkologie und Hämatologie

## Publications (0)

No results found.

## Projects (40)

**A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY TO COMPARE THE EFFICACY AND SAFETY OF ODRONEXTAMAB (REGN1979), AN ANTICD20 X ANTI-CD3 BISPECIFIC ANTIBODY, VERSUS INVESTIGATOR'S CHOICE IN PREVIOUSLY UNTREATED PARTICIPANTS WITH FOLLICULAR LYMPHOMA (OLYMPIA-1)**

*Clinical Studies - Apr 18, 2024 - Dec 31, 2028*

*Completed*

**An Open-label, Dose Escalation, Phase 1/2 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of TAK-676 as a Single Agent and in Combination With Pembrolizumab in Adult Patients With Advanced or Metastatic Solid Tumors**

*Clinical Studies - Mar 25, 2024 - Dec 31, 2028*

*Ongoing*

**Phase 2/3 Randomized Study of Tebentafusp as Monotherapy and in Combination with Pembrolizumab Versus Investigator's Choice in HLA-A\*02:01-positive Participants with Previously Treated Advanced Melanoma (TEBE-AM)**

*Clinical Studies - Jan 26, 2024 - Dec 31, 2027*

*Ongoing*

**A single-arm phase II trial of the addition of niraparib to anti-PD-L1 antibody maintenance in patients with SLFN11-positive, extensive-disease small cell lung cancer.**

*Clinical Studies - Dec 21, 2023 - Dec 31, 2027*

*Ongoing*

**A Phase III, Randomized, Open-Label, Multicenter, Global Study of Volrustomig (MEDI5752) in Combination with Carboplatin plus Pemetrexed Versus Platinum plus Pemetrexed or Nivolumab plus Ipilimumab in Participants with Unresectable Pleural Mesothelioma (eVOLVE-Meso)**

*Clinical Studies - Nov 17, 2023 - Dec 31, 2028*

*Ongoing*

**A Phase 3 Randomized Study Comparing Teclistamab in Combination with Daratumumab SC and Lenalidomide (Tec-DR) versus Daratumumab SC, Lenalidomide, and Dexamethasone (DRd) in Participants with Newly Diagnosed Multiple Myeloma Who are Either Ineligible or not Intended for Autologous Stem Cell Transplant as Initial Therapy**

*Clinical Studies - Nov 3, 2023 - Dec 1, 2028*

*Ongoing*

**A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors**

*Clinical Studies - Oct 30, 2023 - Dec 31, 2026*

*Ongoing*

**A double-blind randomised phase III trial evaluating the efficacy of ADT +/- darolutamide in de novo metastatic prostate cancer patients with vulnerable functional ability and not elected for docetaxel or androgen receptor targeted agents**

*Clinical Studies - Oct 18, 2023 - Dec 31, 2028*

*Ongoing*

**A Randomized, Open-label, Phase 3 Study of Tarlatamab Compared With Standard of Care in Subjects with Relapsed Small Cell Lung Cancer After Platinum-based First Line chemotherapy (DeLLphi-304)**

*Clinical Studies - Jul 17, 2023 - Dec 31, 2025*

*Ongoing*

**Studie zur Untersuchung, wie gut die Behandlung mit dem Antikörper-Konjugat Sacituzumab Govitecan wirkt bei Frauen mit frühem, HER2-negativem Brustkrebs und ho-hem Rückfallrisiko nach einer medikamentösen Vorbehandlung und Operation im Vergleich zu schon bekannten Therapien**

*Clinical Studies - Apr 26, 2023 - Dec 31, 2026*

*Ongoing*

**A multicentre single-arm phase II trial of amivantamab, lazertinib plus bevacizumab in patients with EGFR-mutant advanced NSCLC with progression on previous third-generation EGFR-TKI**

*Clinical Studies - Mar 14, 2023 - Dec 31, 2030*

*Ongoing*

**A Dose-Escalation and Expansion Study of the Safety and Efficacy of XL092 in Combination with Immuno-Oncology Agents in Subjects with Unresectable Advanced or Metastatic Solid Tumors**

*Clinical Studies - Feb 7, 2023 - Dec 31, 2026*

*Ongoing*

**A Phase 1, Open-label, Multicenter Study to Assess Safety, Tolerability, PK, and Efficacy of MK-6598 as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors**

*Clinical Studies - Feb 1, 2023 - Dec 31, 2028*

*Ongoing*

**A Phase 1/1b Open-label, Multicenter Clinical Study of MK-0472 as Monotherapy and Combination Therapy in Participants with Advanced/Metastatic Solid Tumors**

*Clinical Studies - Jan 11, 2023 - Dec 31, 2028*

*Ongoing*

**CA209-6K7 - Intrathecal administration of anti-PD1/anti-CTLA-4 in combination with systemic combination of anti-PD1/anti-CTLA-4 in patients with NSCLC without oncogenic driver mutation or melanoma and newly diagnosed leptomeningeal metastasis: a multicentric phase I study**

*Clinical Studies - Dec 9, 2022 - Dec 31, 2027*

*Ongoing*

**A Phase 1 Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 509 in Subjects With Metastatic Castration-resistant Prostate Cancer**

*Clinical Studies - Nov 30, 2022 - Dec 31, 2026*

*Ongoing*

**A Randomized, Open-label, Phase 3 Study of Sacituzumab Govitecan and Pembrolizumab Versus Treatment of Physician's Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced, Inoperable, or Metastatic Triple-Negative Breast Cancer, Whose Tumors Express PD-L1**

*Clinical Studies - Nov 28, 2022 - Dec 31, 2026*

*Ongoing*

**IP-001\_RFA (IP-IIO-622): Intratumoral injection of IP-001 following thermal ablation in patients with advanced solid tumors. A multicenter Phase 1b/2a trial in colorectal cancer, non-small cell lung cancer, and soft tissue sarcoma patients**

*Clinical Studies - Nov 8, 2022 - Dec 31, 2024*

*Ongoing*

**A Phase 3 Randomized Study Comparing Bortezomib, Lenalidomide and Dexamethasone (VRd) followed by Ciltacabtagene Autoleucel, a Chimeric Antigen Receptor T cell (CAR-T) Therapy Directed Against BCMA versus Bortezomib, Lenalidomide, and Dexamethasone (VRd) followed by Lenalidomide and Dexamethasone (Rd) Therapy in Participants with Newly Diagnosed Multiple Myeloma for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy**

*Clinical Studies - Sep 16, 2022 - Dec 31, 2032*

*Ongoing*

**A Randomized, Open-label, Phase 3 Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Patients With Previously Untreated, Locally Advanced, Inoperable or Metastatic Triple-Negative Breast Cancer Whose Tumors Do Not Express PD-L1 or in Patients Previously Treated With Anti-PD-(L)1 Agents in the Early Setting Whose Tumors do Express PD-L1**

*Clinical Studies - Sep 9, 2022 - Dec 31, 2026*

*Ongoing*

**CATALYM CTL-002-001 A PHASE 1/2, FIRST-IN-HUMAN, TWO-PART, OPEN-LABEL CLINICAL TRIAL OF INTRAVENOUS ADMINISTRATION OF CTL-002 GIVEN AS MONOTHERAPY AND/OR IN COMBINATION WITH AN ANTI-PD-1 CHECKPOINT INHIBITOR IN SUBJECTS WITH ADVANCED-STAGE, RELAPSED/REFRACTORY SOLID TUMORS**

*Clinical Studies - Sep 2, 2022 - Sep 8, 2030*

*Completed*

**SPECTA: Screening Cancer Patients for Efficient Clinical Trial Access**

*Clinical Studies - Aug 9, 2022 - Dec 31, 2027*

*Ongoing*

**A Phase 1/Phase 2 Study to Evaluate the Safety and Tolerability of MK-1088 as Monotherapy and in Combination with Pembrolizumab in Participants with Advanced Solid Tumors**

*Clinical Studies - Jul 8, 2022 - Dec 31, 2025*

*Ongoing*

**ANV419 Single Agent (Parts A-C) or Combination (Part D) First in Human Study Phase 1/2: Open-label, Dose Escalation and Expansion Study in Patients with Relapsed/Refractory Advanced Solid Tumors and Multiple Myeloma. (Anaveon)**

*Clinical Studies - Mar 3, 2022 - Mar 2, 2024*

*Automatically Closed*

**A Phase III, randomised, Open-Label, multicenter study evaluating the efficacy and safety of adjuvant GDC-9545 compared with physician's choice of adjuvant endocrine Monotherapy in patients with Estrogen Receptor-Positive, HER2-Negative Early Breast Cancer**

*Clinical Studies - Mar 1, 2022 - Jul 26, 2030*

*Ongoing*

**A Phase 1, Open-Label, Multicenter Study to Assess Safety, Tolerability, PK, and Efficacy of MK-1084 as Monotherapy and in Combination with Pembrolizumab in Subjects with KRASG12C Mutant Advanced Solid Tumors**

*Clinical Studies - Jan 13, 2022 - Mar 2, 2027*

*Ongoing*

**A phase 3, multicenter, open-label, randomized, study of gilteritinib versus midostaurin in combination with induction and consolidation therapy followed by one-year maintenance in patients with newly diagnosed Acute Myeloid Leukemia (AML) or Myelodysplastic syndromes with excess blasts-2 (MDS-EB2) with FLT3 mutations eligible for intensive chemotherapy**

*Clinical Studies - Oct 13, 2021 - Jul 26, 2028*

*Ongoing*

**SAKK 15/19 Thoracic radiotherapy plus maintenance Durvalumab after first line Carboplatin and Etoposide plus Durvalumab in extensive-stage disease small cell lung cancer (EDSCLC) A multicenter single arm open label phase II trial**

*Clinical Studies - Jun 24, 2021 - Jun 28, 2027*

*Ongoing*

**Assessing a ctDNA and PET-oriented therapy in patients with DLBCL multicenter, open-label, phase II trial**

*Clinical Studies - Jun 8, 2021 - Dec 31, 2030*

*Ongoing*

**ON-TRK: Prospective Non-interventional study in patients with locally advanced or metastatic TRK fusion cancer treated with larotrectinib**

*Clinical Studies - Apr 14, 2021 - Dec 31, 2025*

*Ongoing*

**MK-7902-005 A Multicenter, Open-label Phase 2 Study of Lenvatinib (E7080/MK-7902) Plus Pembrolizumab (MK-3475) in Previously Treated Subjects with Selected Solid Tumors (LEAP-005)**

*Clinical Studies - Mar 17, 2021 - May 7, 2030*

*Ongoing*

**A Phase II, Open-Label, Multicenter Study Evaluating The Safety And Efficacy Of Neoadjuvant And Adjuvant Tiragolumab Plus Atezolizumab, With Or Without Platinum-Based Chemotherapy, In Patients With Previously Untreated Locally Advanced Resectable Stage II, IIA, Or Select IIIB Non-Small Cell Lung Cancer**

*Clinical Studies - Feb 12, 2021 - Dec 31, 2026*

*Ongoing*

**Intratumoral injection of IP-001 following thermal ablation in patients with advanced solid tumors. A multicenter phase Ib/IIa trial with expansion cohorts in melanoma and soft tissue sarcoma patients**

*Clinical Studies - Oct 7, 2020 - Dec 31, 2024*

*Ongoing*

**Vacuum assisted biopsy Immediately before Surgery as an Intra- or pre-Operative surrogate for patient response to Neoadjuvant chemotherapy for breast cancer (VISION I) A multicenter prospective feasibility trial**

*Clinical Studies - Aug 11, 2020 - Dec 31, 2024*

*Ongoing*

**A phase 3, multicenter, double-blind, randomized, placebo-controlled study of ivosidenib or enasidenib in combination with induction therapy and consolidation therapy followed by maintenancetherapy in patients with newly diagnosed acute myeloid leukemia or myelodysplastic syndrome with excess blasts-2, with an IDH1 or IDH2 mutation, respectively, eligible for intensive chemotherapy.**

*Clinical Studies - Dec 18, 2019 - Jan 31, 2027*

*Ongoing*

**ENIGMA: Open label, non-randomized, Phase IB study to characterize safety, tolerability and recommended dose of EDO-S101, a first-in-class alkylating histone deacetylase inhibition (HDACi) fusion molecule, in combination with Nivolumab in patients with refractory, locally advanced or metastatic melanoma**

*Clinical Studies - May 2, 2019 - Dec 31, 2024*

*Ongoing*

**TLD-1, a novel Liposomal Doxorubicin, in Patients with Advanced Solid Tumors; a multicenter open-label single-arm phase I trial.**

*Clinical Studies - Oct 26, 2018 - Dec 31, 2026*

*Ongoing*

**SAKK GRAALL 2014: Multicenter trial for the treatment of Acute Lymphoblastic Leukemia (ALL) in younger adults (18-59 years)**

*Clinical Studies - Jun 3, 2016 - May 31, 2026*

*Ongoing*

**A Randomized multicenter phase III trial comparing enzalutamide vs. a combination of Ra223 and enzalutamide in asymptomatic or mildly symptomatic castration resistant prostate cancer patients metastatic to bone. PEACE III**

*Clinical Studies - Oct 26, 2015 - Dec 31, 2030*

*Ongoing*

**Prevention of symptomatic skeletal events with denosumab administered every 4 weeks versus every 12 weeks: A noninferiority phase III trial (SAKK 96/12, REDUSE)**

*Clinical Studies - Jul 7, 2014 - Dec 31, 2026*

*Ongoing*

---

Kantonsspital St.Gallen

Rorschacher Strasse 95

CH-9007 St.Gallen

T: +41 71 494 11 11

[support.forschung@kssg.ch](mailto:support.forschung@kssg.ch)